21 julio 2011

Yondelis . Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. .

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.

Germano G, Mantovani A, Allavena P.
SourceDepartment of Immunology and Inflammation, IRCCS Humanitas Clinical Institute , Via Manzoni 56, 20089, Rozzano, Milan , Italy.




Abstract :

Different types of cancer take advantage of inflammatory components to improve their life-span in the organs. A sustenance of growth factors and cytokines (e.g. interleukin (IL)-1, tumor necrosis factor, IL-6, vascular endothelial growth factor) supports malignant cell progression and contributes to suppress the body immune defense. Strategies to modulate the host micro-environment offer new approaches for anti-cancer therapies. For these reasons new molecules with anti-tumor and anti-inflammatory features (e.g. trabectedin) are looked at with new eyes in the light of the crucial link between inflammation and cancer.

...